Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 34/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 836 Biotechnology companies, Molecular Partners AG ranks worse than 119617.11% on this metric.
The historical rank and industry rank for Molecular Partners AG's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Molecular Partners AG's highest Days Sales Outstanding was 872.25. The lowest was 1.83. And the median was 21.33.
MLLCF's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.09 * Ranked among companies with meaningful Days Sales Outstanding only.
Molecular Partners AG's Days Sales Outstanding
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Molecular Partners AG (OTCPK:MLLCF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Molecular Partners AG Days Sales Outstanding Related Terms
Molecular Partners AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Days Sales Outstanding Chart
MLLCF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Molecular Partners AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Days Sales Outstanding falls into.
Molecular Partners AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Days Sales Outstanding of 0.00 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Molecular Partners AG and its competitors. Over the past decade, Molecular Partners AG's Days Sales Outstanding has ranged from 1.83 to 872.25. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 836 companies in the Biotechnology industry.
Is Molecular Partners AG's Days Sales Outstanding too high?
Molecular Partners AG's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 872.25. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 836 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 836 companies for Days Sales Outstanding. This places Molecular Partners AG in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Historically, Molecular Partners AG's own Days Sales Outstanding has ranged from 1.83 to 872.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.80 — trading 645.1% above its estimated fair value. The current Days Sales Outstanding is 0.00. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 645.1% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Days Sales Outstanding: 0.00
GF Value™: $0.51 vs. price of $3.80 (645.1% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
